List view / Grid view
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis...
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL...
25 August 2016 | By Novartis
The study included 1,651 people with SPMS randomised to receive either 2mg BAF312 or placebo in a 2:1 ratio respectively, the primary endpoint being an improvement in the time to three-month confirmed disability progression, as measured by the expanded disability status scale (EDSS), versus placebo...
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective.
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
29 June 2016 | By Victoria White, Digital Content Producer
Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination...
28 June 2016 | By Victoria White, Digital Content Producer
The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies...
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
15 June 2016 | By Victoria White, Digital Content Producer
Novartis' KAF156 is one of the first antimalarial drug candidates to enter Phase IIb clinical development in more than 20 years...
10 June 2016 | By Victoria White, Digital Content Producer
Data from the largest study of its kind confirm the long-term safety profile of Novartis’ Revolade in adults with chronic immune thrombocytopenia...
9 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
2 June 2016 | By Victoria White, Digital Content Producer
The EC has approved Afinitor (everolimus) for the treatment of neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease...
